Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE3.2900
- TODAY'S CHANGE (%)-0.0900 (-2.6627%)
- Bid / Lots3.2600/ 1
- Ask / Lots3.2700/ 1
- Open / Previous Close3.4100 / 3.3800
- Day Range
- 52 Week Range
- Volume98,795
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 787 | 3.39 |
| 09:38 ET | 1000 | 3.492 |
| 09:41 ET | 300 | 3.45 |
| 09:52 ET | 1049 | 3.365831 |
| 09:54 ET | 200 | 3.4323 |
| 09:56 ET | 100 | 3.4 |
| 09:57 ET | 100 | 3.4 |
| 09:59 ET | 2000 | 3.35 |
| 10:03 ET | 100 | 3.345 |
| 10:12 ET | 600 | 3.35 |
| 10:14 ET | 773 | 3.335 |
| 10:15 ET | 600 | 3.355 |
| 10:17 ET | 100 | 3.3521 |
| 10:21 ET | 1894 | 3.31 |
| 10:24 ET | 17238 | 3.29 |
| 10:26 ET | 1100 | 3.25 |
| 10:28 ET | 3840 | 3.28 |
| 10:30 ET | 910 | 3.29 |
| 10:32 ET | 121 | 3.29 |
| 10:33 ET | 100 | 3.28 |
| 10:35 ET | 900 | 3.33 |
| 10:48 ET | 277 | 3.3026 |
| 11:00 ET | 275 | 3.29 |
| 11:08 ET | 1800 | 3.278 |
| 11:09 ET | 2200 | 3.274 |
| 11:13 ET | 200 | 3.31 |
| 11:15 ET | 200 | 3.33 |
| 11:18 ET | 100 | 3.35 |
| 11:20 ET | 2479 | 3.355 |
| 11:22 ET | 200 | 3.35 |
| 11:24 ET | 100 | 3.37 |
| 11:36 ET | 200 | 3.3336 |
| 11:40 ET | 12900 | 3.28 |
| 11:44 ET | 1003 | 3.3 |
| 11:47 ET | 500 | 3.3 |
| 11:49 ET | 800 | 3.3 |
| 11:54 ET | 300 | 3.3 |
| 12:00 ET | 3771 | 3.29 |
| 12:02 ET | 300 | 3.276 |
| 12:05 ET | 100 | 3.28 |
| 12:07 ET | 620 | 3.28 |
| 12:09 ET | 200 | 3.28 |
| 12:12 ET | 2859 | 3.2646 |
| 12:14 ET | 287 | 3.26 |
| 12:18 ET | 109 | 3.25 |
| 12:20 ET | 1587 | 3.23 |
| 12:21 ET | 100 | 3.235 |
| 12:23 ET | 696 | 3.23 |
| 12:27 ET | 200 | 3.24 |
| 12:30 ET | 279 | 3.2706 |
| 12:34 ET | 200 | 3.265 |
| 12:36 ET | 400 | 3.2747 |
| 12:38 ET | 200 | 3.27 |
| 12:39 ET | 200 | 3.26 |
| 12:41 ET | 400 | 3.265 |
| 12:45 ET | 250 | 3.2668 |
| 12:48 ET | 200 | 3.249 |
| 12:56 ET | 698 | 3.2613 |
| 01:03 ET | 100 | 3.26 |
| 01:12 ET | 100 | 3.234 |
| 01:14 ET | 400 | 3.25 |
| 01:15 ET | 7022 | 3.295 |
| 01:17 ET | 100 | 3.29 |
| 01:19 ET | 4322 | 3.26 |
| 01:21 ET | 600 | 3.3 |
| 01:24 ET | 6171 | 3.25 |
| 01:30 ET | 122 | 3.2788 |
| 01:32 ET | 400 | 3.27 |
| 01:33 ET | 100 | 3.27 |
| 01:42 ET | 200 | 3.252 |
| 01:50 ET | 300 | 3.2684 |
| 01:51 ET | 100 | 3.29 |
Sep 17, 2024
DJ Relmada Therapeutics Raised to Buy From Hold by Jefferies, from 8:56AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:56AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm, from 9:36PM ET on Monday Sep 16, 2024 by Dow Jones
9:36PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 5, 2024
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm, from 9:29AM ET on Thursday Sep 05, 2024 by Dow Jones
9:29AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 102.0M | -1.1x | --- |
Checkpoint Therapeutics Inc | 100.8M | -1.5x | --- |
Annovis Bio Inc | 103.9M | -1.8x | --- |
Anixa Biosciences Inc | 101.4M | -7.9x | --- |
Leap Therapeutics Inc | 99.9M | -1.3x | --- |
Regulus Therapeutics Inc | 104.1M | -1.3x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $102.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-2.88 |
Book Value | $2.84 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
